Milestone Pharmaceuticals stock faces earnings update on November 13

Published on 11/12/2026 at 03:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Milestone Pharmaceuticals stock heads toward a third-quarter update on Friday. Management will discuss results and CARDAMYST before the market opens.

What Investors Should Watch Next

The report covers the quarter ended September 30, 2026.
Milestone will discuss its business update before the market opens.
CARDAMYST is FDA-approved for acute symptomatic PSVT episodes, while etripamil is also in Phase 3 development for AFib.

MIST, CA59935V1076, Illustration mit AI erstellt.

Milestone Pharmaceuticals will report its third-quarter 2026 financial results on Friday, November 13, before the US market opens. The company announced the schedule on November 3 and said the quarter ended September 30, 2026. A conference call and webcast are set for 8:30 a.m. Eastern Time, according to Milestone Pharmaceuticals.

Results will test launch progress

The update will give investors the next scheduled look at the commercial-stage company's performance and operating priorities. Management is expected to discuss the business alongside the quarterly figures, making the call a near-term catalyst for shareholders tracking the rollout of CARDAMYST.

CARDAMYST leads the portfolio

Milestone describes CARDAMYST, its lead product, as a nasal spray containing etripamil, a calcium channel blocker. The product is FDA-approved to convert acute symptomatic episodes of paroxysmal supraventricular tachycardia, or PSVT, to sinus rhythm in adults. Etripamil is also in Phase 3 development for the control of symptomatic episodic attacks associated with atrial fibrillation.

Milestone Pharmaceuticals in focus

Milestone Pharmaceuticals is a commercial-stage biopharmaceutical company headquartered in Montreal, Canada, with operations also based in Charlotte, North Carolina. It develops and commercializes cardiovascular medicines for people living with certain heart conditions. Its lead program combines the approved CARDAMYST product with further clinical development of etripamil for atrial fibrillation.